CRA consultant Becky Davis recently presented “GLP-1s: Riding the Wave of Innovative Medications” at Asembia’s AXS25 Summit, which looked at the evolution of the GLP-1 category, and what might be in store for future payer management.
Navigating the evolving landscape for psychedelic therapies
These substances may offer innovative treatment options for psychiatric conditions including PTSD, major and treatment-resistant depression, generalized...